PCN191 - Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC)

Saved in:

Bibliographic Details
Published in	Value in health Vol. 17; no. 7; p. A648
Main Authors	Ghatnekar, O., Nørgaard, K., Skaltsa, K.
Format	Journal Article
Language	English
Published	Elsevier Inc 01.11.2014
Online Access	Get full text

Loading…

More Information
ISSN:	1098-3015 1524-4733
DOI:	10.1016/j.jval.2014.08.2350